ATE397602T1 - 9-(piperazinylalkyl)carbazole als bax-modulatoren - Google Patents

9-(piperazinylalkyl)carbazole als bax-modulatoren

Info

Publication number
ATE397602T1
ATE397602T1 AT00968161T AT00968161T ATE397602T1 AT E397602 T1 ATE397602 T1 AT E397602T1 AT 00968161 T AT00968161 T AT 00968161T AT 00968161 T AT00968161 T AT 00968161T AT E397602 T1 ATE397602 T1 AT E397602T1
Authority
AT
Austria
Prior art keywords
carbazole
piperazine derivatives
piperazinylalkyl
carbazoles
modulators
Prior art date
Application number
AT00968161T
Other languages
English (en)
Inventor
Serge Halazy
Dennis Church
Bruno Antonsson
Agnes Bombrun
Patrick Gerber
Jean-Claude Martinou
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE397602T1 publication Critical patent/ATE397602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
AT00968161T 1999-10-18 2000-10-18 9-(piperazinylalkyl)carbazole als bax-modulatoren ATE397602T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99810944A EP1094063A1 (de) 1999-10-18 1999-10-18 9-(Piperazinylalkyl)carbazole als Bax-Modulatoren

Publications (1)

Publication Number Publication Date
ATE397602T1 true ATE397602T1 (de) 2008-06-15

Family

ID=8243090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968161T ATE397602T1 (de) 1999-10-18 2000-10-18 9-(piperazinylalkyl)carbazole als bax-modulatoren

Country Status (10)

Country Link
US (2) US8053436B1 (de)
EP (2) EP1094063A1 (de)
JP (1) JP5053492B2 (de)
AT (1) ATE397602T1 (de)
AU (1) AU780742B2 (de)
CA (1) CA2385456C (de)
DE (1) DE60039125D1 (de)
ES (1) ES2304354T3 (de)
IL (1) IL149163A0 (de)
WO (1) WO2001029028A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125925A1 (de) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amin-Derivate zur Behandlung von Apoptosis
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
US7723722B2 (en) * 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102405043B (zh) * 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9040567B2 (en) 2011-08-19 2015-05-26 Emory University BAX agonist, compositions, and methods related thereto
EP2755656B1 (de) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771005B1 (de) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
EP2773206B1 (de) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AU2012338362B2 (en) * 2011-11-15 2017-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR101686076B1 (ko) 2012-07-04 2016-12-13 제일모직주식회사 유기발광소자용 조성물, 이를 포함하는 유기발광층 및 유기발광소자
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN108329253A (zh) * 2012-08-24 2018-07-27 得克萨斯州大学系统董事会 前神经原性化合物
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2925322B1 (de) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014108168A1 (en) 2013-01-10 2014-07-17 Merck Patent Gmbh Piperidinylcarbazole as antimalarial
EP2956142B1 (de) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN106573918B (zh) 2014-07-04 2020-06-16 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物
US11938128B2 (en) 2017-03-10 2024-03-26 Albert Einstein College Of Medicine Small molecule BAX inhibitors and uses thereof
MX2020006892A (es) * 2017-12-31 2020-11-11 Evergreen Biosciences Composiciones para crioconservación y métodos de uso de estas.
CN109369510A (zh) * 2018-10-31 2019-02-22 云南大学 具有抗hiv活性的双甲氧基取代咔唑类化合物制备及用途
US20220296604A1 (en) * 2019-08-08 2022-09-22 New York University Indole compounds as modulators of rage activity and uses thereof
KR102093409B1 (ko) * 2019-10-23 2020-03-25 고려대학교 산학협력단 카바졸 화합물을 유효성분으로 포함하는 항진균 조성물
WO2023023316A1 (en) * 2021-08-20 2023-02-23 Albert Einstein College Of Medicine Compositions for organ and tissue preservation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE537690A (de) * 1954-07-01
ZA787352B (en) 1978-11-01 1980-08-27 Wellcome Found Pharmacologically active heterocyclic compounds and their use in medicine
PH14576A (en) 1978-11-01 1981-09-24 Wellcome Found 9-(3-(3,5-cis-dimethylpiperazino)prophyl)carrazole,salts and solvates thereof and pharmaceutical compositions containing same
SU1584341A1 (ru) * 1989-02-06 1995-03-20 Институт физико-органической химии и углехимии АН УССР Производные 1-[(3-хлоркарбазолил-9)-3-(2-оксипропил)]-пиперазина, проявляющие анксиолитическую активность
JPH03251564A (ja) * 1990-02-26 1991-11-11 Taisho Pharmaceut Co Ltd ジメチルカルバゾール誘導体
JPH06228095A (ja) * 1993-02-04 1994-08-16 Kirin Brewery Co Ltd カルバゾール誘導体
ATE382061T1 (de) * 1994-08-30 2008-01-15 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
US5770690A (en) * 1995-06-27 1998-06-23 Neurex Corporation Bax omega protein and methods
DE19538485C2 (de) 1995-10-17 1998-08-06 Dorma Gmbh & Co Kg Verriegelungsvorrichtung für eine ortsveränderliche Wand
US5733911A (en) * 1996-01-26 1998-03-31 Hitachi Chemical Co., Ltd. Method for inducing death of neoplastic cells using piperazne derivatives
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
JP3251564B2 (ja) * 1999-09-30 2002-01-28 コングロエンジニアリング株式会社 コンクリート捨て型枠用コルゲート鉄板パネル及び該型枠の施工方法

Also Published As

Publication number Publication date
ES2304354T3 (es) 2008-10-16
JP2003512371A (ja) 2003-04-02
AU780742B2 (en) 2005-04-14
EP1237887B1 (de) 2008-06-04
CA2385456C (en) 2012-01-17
US8410110B2 (en) 2013-04-02
AU7811200A (en) 2001-04-30
JP5053492B2 (ja) 2012-10-17
IL149163A0 (en) 2002-11-10
EP1237887A1 (de) 2002-09-11
US20120040933A1 (en) 2012-02-16
DE60039125D1 (de) 2008-07-17
US8053436B1 (en) 2011-11-08
EP1094063A1 (de) 2001-04-25
WO2001029028A1 (en) 2001-04-26
CA2385456A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
ATE397602T1 (de) 9-(piperazinylalkyl)carbazole als bax-modulatoren
PT1263730E (pt) Derivados amina para o tratamento de apoptose
ME00513B (me) Azabicikloalkani kao modulatori ccr5
YU40701A (sh) Piperidini kao modulatori ccr5
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
UY24555A1 (es) Nuevos compuestos
BRPI0406801A (pt) Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
PT1263724E (pt) Novos compostos
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE429210T1 (de) Orale flüssige zusammensetzungen
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
NO992780D0 (no) Forbedrede farmas°ytiske preparater
DK1319000T3 (da) Anvendelse af 1-azabicyclo(2,2,2)oktan-3-on-derivater til behandling af cancertumorer
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
ATE253359T1 (de) Antithrombotische mittel
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
HUP0301257A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és topoizomeráz I és II inhibitorokat tartalmazó kombinált tumorellenes kompozíciók
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
HUP0301234A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és alkilezőszereket tartalmazó kombinált tumorellenes kompozíciók
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties